Anika Therapeutics Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
235
- Stock Symbol
-
ANIK
- Investments
-
3
- Share Price
-
$13.38
- (As of Friday Closing)
Anika Therapeutics General Information
Description
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Contact Information
Corporate Office
- 32 Wiggins Avenue
- Bedford, MA 01730
- United States
Corporate Office
- 32 Wiggins Avenue
- Bedford, MA 01730
- United States
Anika Therapeutics Stock Performance
As of 13-Nov-2026, Anika Therapeutics’s stock price is $13.38. Its current market cap is $179M with 13.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.38 | $13.81 | $9.01 - $22.88 | $179M | 13.4M | 106K | -$0.13 |
Anika Therapeutics Financials Summary
As of 30-Sep-2026, Anika Therapeutics has a trailing 12-month revenue of $123M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 249,947 | 105,105 | 206,233 | 290,418 |
| Revenue | 123,431 | 112,819 | 119,907 | 120,792 |
| EBITDA | 3,069 | (5,322) | 3,020 | 15,061 |
| Net Income | (1,766) | (10,880) | (56,385) | (82,667) |
| Total Assets | 189,600 | 190,270 | 202,740 | 270,632 |
| Total Debt | 26,149 | 26,248 | 25,932 | 27,742 |
Anika Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anika Therapeutics Comparisons
Industry
Financing
Details
Anika Therapeutics Competitors (3)
One of Anika Therapeutics’s 3 competitors is Orthofix Medical, a Formerly PE-Backed company based in Lewisville, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orthofix Medical | Formerly PE-Backed | Lewisville, TX | ||||
| NovaBone | Private Equity-Backed | Alachua, FL | ||||
| Spinal Simplicity | Venture Capital-Backed | Overland Park, KS |
Anika Therapeutics Patents
Anika Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250241759-A1 | Implant securing systems for tissue repair and method thereof | Pending | 25-Jan-2024 | ||
| WO-2025160573-A1 | Implant securing systems for tissue repair and method thereof | Pending | 25-Jan-2024 | ||
| WO-2025109556-A1 | Rotator cuff system | Inactive | 22-Nov-2023 | ||
| EP-4559410-A1 | Surgical tools and systems | Pending | 22-Nov-2023 | ||
| US-20250000637-A1 | Surgical tools, systems, and methods | Pending | 30-Jun-2023 | A61F2/0805 |
Anika Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Anika Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Anika Therapeutics Acquisitions (3)
Anika Therapeutics’s most recent deal was a Merger/Acquisition with Arthrosurface for . The deal was made on 03-Feb-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arthrosurface | 03-Feb-2020 | Merger/Acquisition | Therapeutic Devices | ||
| Parcus Medical | 24-Jan-2020 | Merger/Acquisition | Therapeutic Devices | ||
| Fidia Advanced Biopolymers | 31-Dec-2009 | Merger/Acquisition | Pharmaceuticals |
Anika Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
20.06 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Supplies
Subindustry
of 60
Rank
Percentile
Anika Therapeutics Exits (2)
Anika Therapeutics’s most recent exit was on 03-Feb-2020 from Arthrosurface. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Arthrosurface | 03-Feb-2020 | Completed |
|
||
| Parcus Medical | 24-Jan-2020 | Merger/Acquisition | Completed |
Anika Therapeutics FAQs
-
When was Anika Therapeutics founded?
Anika Therapeutics was founded in 1992.
-
Where is Anika Therapeutics headquartered?
Anika Therapeutics is headquartered in Bedford, MA.
-
What is the size of Anika Therapeutics?
Anika Therapeutics has 235 total employees.
-
What industry is Anika Therapeutics in?
Anika Therapeutics’s primary industry is Therapeutic Devices.
-
Is Anika Therapeutics a private or public company?
Anika Therapeutics is a Public company.
-
What is Anika Therapeutics’s stock symbol?
The ticker symbol for Anika Therapeutics is ANIK.
-
What is the current stock price of Anika Therapeutics?
As of 13-Nov-2026 the stock price of Anika Therapeutics is $13.38.
-
What is the current market cap of Anika Therapeutics?
The current market capitalization of Anika Therapeutics is $179M.
-
What is Anika Therapeutics’s current revenue?
The trailing twelve month revenue for Anika Therapeutics is $123M.
-
Who are Anika Therapeutics’s competitors?
Orthofix Medical, NovaBone, and Spinal Simplicity are competitors of Anika Therapeutics.
-
What is Anika Therapeutics’s annual earnings per share (EPS)?
Anika Therapeutics’s EPS for 12 months was -$0.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
